Junshi Biosciences and TopAlliance are set to enter a collaboration with LEO Pharma to distribute and market toripalimab in ...

Junshi Biosciences enters distribution and marketing partnership with LEO Pharma for toripalimab in Europe: Shanghai, China Wednesday, January 22, 2025, 14:00 Hrs [IST] Shanghai J ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

Junshi Biosciences SHANGHAI, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical ...

General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, “Toripalimab has made significant strides in its internationalization. As of today, toripalimab has been approved in 35 countries ...

Shanghai Junshi Biosciences Co., Ltd. announced that its drug toripalimab has received regular approval from the National Medical Products Administration for the treatment of unresectable or ...

01877 JUNSHI BIO Announcements and Notices - (Profit Warning / Inside Information) 01877 JUNSHI BIO Announcements and Notices - (Overseas Regulatory Announcement - Oth 01919 COSCO SHIP HOLD Next Day ...

Shanghai Junshi Biosciences Co., Ltd. announced that its investigational new drug application for JS212 injection has been accepted by the National Medical Products Administration. JS212 is a ...

Short interest in Shanghai Junshi Biosciences Co Ltd (OTC:SHJBF) increased during the last reporting period, rising from 1.11M to 1.11M. This put -% of the company's publicly available shares short.

SHANGHAI, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...

SHANGHAI, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to ...